Suppr超能文献

低氧会增加真性红细胞增多症血栓形成并发症的发生率吗?

Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?

作者信息

Zangari Maurizio, Fink Louis, Tolomelli Giulia, Lee Jasmine C H, Stein Brady L, Hickman Kimberly, Swierczek Sabina, Kelley Todd W, Berno Tamara, Moliterno Alison R, Spivak Jerry L, Gordeuk Victor R, Prchal Josef T

机构信息

Division of Hematology, University of Utah, Salt Lake City, UT 84132, USA.

出版信息

Blood Coagul Fibrinolysis. 2013 Apr;24(3):311-6. doi: 10.1097/MBC.0b013e32835bfdb9.

Abstract

Thromboses represent a major cause of morbidity and mortality in polycythemia vera but the contributing mechanisms are not fully described. To evaluate whether environmental conditions such as altitude/hypoxia could impact thrombosis history, we retrospectively analyzed thrombosis history in 71 polycythemia vera patients living at an elevation of 5000 feet or more in the Salt Lake City (SLC) area and 166 polycythemia vera patients living near sea level in the Baltimore (BLM) area. The SLC cohort was older with a longer disease duration. No significant differences in type of anticoagulation therapy or prothrombotic factors were present between the two cohorts. After adjusting for age, sex and disease duration, SLC patients experienced an estimated 3.9-fold increase in the odds of a history of thrombosis compared with BLM patients (95% confidence interval 1.8-7.6; P=0.0004). A history of a cardiovascular event was present in 58% of the SLC patients compared with 27% of the BLM patients (P<0.0001). Before diagnosis, thrombosis occurred in 18 and 4% of the SLC and BLM groups, respectively (P=0.003). No correlation between the JAK2 allele burden and thrombosis was observed in this study. This retrospective study suggests that even moderate hypoxia associated with 5000 feet elevation should be considered as an independent prothrombotic risk factor. This observation needs to be confirmed by prospective studies.

摘要

血栓形成是真性红细胞增多症发病和死亡的主要原因,但相关机制尚未完全阐明。为评估海拔/低氧等环境条件是否会影响血栓形成病史,我们回顾性分析了盐湖城(SLC)地区海拔5000英尺及以上的71例真性红细胞增多症患者和巴尔的摩(BLM)地区海平面附近的166例真性红细胞增多症患者的血栓形成病史。SLC队列患者年龄较大,病程较长。两组在抗凝治疗类型或促血栓形成因素方面无显著差异。在调整年龄、性别和病程后,与BLM患者相比,SLC患者有血栓形成病史的几率估计增加了3.9倍(95%置信区间1.8 - 7.6;P = 0.0004)。58%的SLC患者有心血管事件病史,而BLM患者为27%(P < 0.0001)。诊断前,SLC组和BLM组分别有18%和4%的患者发生血栓形成(P = 0.003)。本研究未观察到JAK2等位基因负荷与血栓形成之间的相关性。这项回顾性研究表明,即使是与海拔5000英尺相关的中度低氧也应被视为独立的促血栓形成危险因素。这一观察结果需要前瞻性研究加以证实。

相似文献

1
Could hypoxia increase the prevalence of thrombotic complications in polycythemia vera?
Blood Coagul Fibrinolysis. 2013 Apr;24(3):311-6. doi: 10.1097/MBC.0b013e32835bfdb9.
4
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
5
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.
Blood. 2007 Aug 1;110(3):840-6. doi: 10.1182/blood-2006-12-064287. Epub 2007 Mar 22.
7
JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis.
Haematologica. 2007 Dec;92(12):1717-8. doi: 10.3324/haematol.12011.
8
Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
Ann Intern Med. 1995 Nov 1;123(9):656-64. doi: 10.7326/0003-4819-123-9-199511010-00003.
10
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24.

引用本文的文献

1
Increased occurrence of migraine aura and susceptibility to spreading depolarizations at altitude.
medRxiv. 2025 Aug 13:2025.08.09.25333153. doi: 10.1101/2025.08.09.25333153.
2
Diagnosis and Treatment of Polycythemia Vera: A Review.
JAMA. 2025 Jan 14;333(2):153-160. doi: 10.1001/jama.2024.20377.
3
Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis.
Ann Hematol. 2024 Jun;103(6):1947-1965. doi: 10.1007/s00277-024-05754-4. Epub 2024 Apr 23.
4
Are coagulation profiles in Andean highlanders with excessive erythrocytosis favouring hypercoagulability?
Exp Physiol. 2024 Jun;109(6):899-914. doi: 10.1113/EP091670. Epub 2024 Mar 30.
5
The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors.
Clin Kidney J. 2023 Aug 17;16(10):1563-1579. doi: 10.1093/ckj/sfad105. eCollection 2023 Oct.
6
Chronic high-altitude exposure and the epidemiology of ischaemic stroke: a systematic review.
BMJ Open. 2022 Apr 29;12(4):e051777. doi: 10.1136/bmjopen-2021-051777.
8
Stroke-Related Mortality at Different Altitudes: A 17-Year Nationwide Population-Based Analysis From Ecuador.
Front Physiol. 2021 Sep 30;12:733928. doi: 10.3389/fphys.2021.733928. eCollection 2021.
9
COVID-19 and the liver: an adverse outcome pathway perspective.
Toxicology. 2021 May 15;455:152765. doi: 10.1016/j.tox.2021.152765. Epub 2021 Mar 23.
10
D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review.
ERJ Open Res. 2020 Jul 13;6(2). doi: 10.1183/23120541.00260-2020. eCollection 2020 Apr.

本文引用的文献

1
Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.
Thrombosis. 2011;2011:874146. doi: 10.1155/2011/874146. Epub 2011 Jul 24.
2
Genetic determinants of Tibetan high-altitude adaptation.
Hum Genet. 2012 Apr;131(4):527-33. doi: 10.1007/s00439-011-1109-3. Epub 2011 Nov 9.
5
Polycythemia vera.
Intern Emerg Med. 2010 Oct;5(5):375-84. doi: 10.1007/s11739-010-0369-6. Epub 2010 Mar 16.
6
Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
Int J Hematol. 2010 Mar;91(2):174-9. doi: 10.1007/s12185-010-0529-5. Epub 2010 Feb 27.
7
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera.
Exp Hematol. 2009 Sep;37(9):1016-21. doi: 10.1016/j.exphem.2009.06.006. Epub 2009 Jun 24.
8
Concordance of assays designed for the quantification of JAK2V617F: a multicenter study.
Haematologica. 2009 Jan;94(1):38-45. doi: 10.3324/haematol.13486. Epub 2008 Nov 10.
9
Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Semin Thromb Hemost. 2007 Jun;33(4):321-9. doi: 10.1055/s-2007-976166.
10
Two routes to functional adaptation: Tibetan and Andean high-altitude natives.
Proc Natl Acad Sci U S A. 2007 May 15;104 Suppl 1(Suppl 1):8655-60. doi: 10.1073/pnas.0701985104. Epub 2007 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验